Metagenomi (NASDAQ:MGX – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.01), Zacks reports. Metagenomi had a negative net margin of 134.27% and a negative return on equity of 43.23%. During the same period in the previous year, the business posted ($20.05) EPS.
Metagenomi Stock Performance
Shares of MGX stock opened at $1.88 on Tuesday. Metagenomi has a fifty-two week low of $1.61 and a fifty-two week high of $11.86. The stock’s 50-day simple moving average is $2.49 and its 200-day simple moving average is $2.51.
Institutional Investors Weigh In On Metagenomi
A hedge fund recently raised its stake in Metagenomi stock. Bank of America Corp DE increased its position in shares of Metagenomi, Inc. (NASDAQ:MGX – Free Report) by 482.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,113 shares of the company’s stock after purchasing an additional 17,491 shares during the quarter. Bank of America Corp DE owned 0.06% of Metagenomi worth $76,000 as of its most recent SEC filing.
Analysts Set New Price Targets
Check Out Our Latest Report on Metagenomi
About Metagenomi
Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.
Read More
- Five stocks we like better than Metagenomi
- What Investors Must Know About Over-the-Counter (OTC) Stocks
- Is Intuitive Machines a Buy After Athena’s Disappointing Landing?
- What Does Downgrade Mean in Investing?
- Joby Aviation Stock: Virgin Atlantic Deal Signals Big Potential
- Using the MarketBeat Dividend Yield Calculator
- Kohl’s Posts Another Kitchen Sink Quarter, But New CEO Has a Plan
Receive News & Ratings for Metagenomi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metagenomi and related companies with MarketBeat.com's FREE daily email newsletter.